Ceftolozane/Tazobactam for the Treatment of Adults With Cystic Fibrosis: Results From a French Prospective Cohort Study.

ABSTRACT:

Background

People with cystic fibrosis (pwCF) are particularly susceptible to respiratory infections, including those caused by multidrug-resistant (MDR) pathogens. Ceftolozane/tazobactam (C/T) is an antibacterial agent combination active against MDR gram-negative bacteria that has shown promising results in isolates from pwCF. This subanalysis is the first extensive observation of real-world C/T use in pwCF.

Methods

The multicenter observational CONDUCT study included consecutive patients, some with cystic fibrosis, who received ≥1 dose of C/T at 28 centers throughout France. Patients were treated according to hospital standards and followed up until the end of C/T treatment (EOT).

Results

Among 260 patients who had received ≥1 dose of C/T, 63 were pwCF, including 12

SUBMITTER: Burgel PR 

PROVIDER: S-EPMC11303002 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature